140 related articles for article (PubMed ID: 2981270)
1. Augmentation of immunity to herpes simplex virus by in vivo administration of interleukin 2.
Rouse BT; Miller LS; Turtinen L; Moore RN
J Immunol; 1985 Feb; 134(2):926-30. PubMed ID: 2981270
[TBL] [Abstract][Full Text] [Related]
2. Cellular interactions in the cytotoxic T lymphocyte response to herpes simplex virus antigens: differential antigen activation requirements for the helper T lymphocyte and cytotoxic T lymphocyte precursors.
Schmid DS; Rouse BT
J Immunol; 1983 Jul; 131(1):479-84. PubMed ID: 6223080
[TBL] [Abstract][Full Text] [Related]
3. Heteroconjugate antibodies enhance cell-mediated anti-herpes simplex virus immunity.
Paya CV; McKean DJ; Segal DM; Schoon RA; Showalter SD; Leibson PJ
J Immunol; 1989 Jan; 142(2):666-71. PubMed ID: 2536060
[TBL] [Abstract][Full Text] [Related]
4. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. II. Bifunctional clones with cytotoxic and virus-induced proliferative activities exhibit herpes simplex virus type 1 and 2 specific or type common reactivities.
Yasukawa M; Zarling JM
J Immunol; 1984 Nov; 133(5):2736-42. PubMed ID: 6207243
[TBL] [Abstract][Full Text] [Related]
5. Effect of rabbit anti-asialo GM1 treatment in vivo or with anti-asialo GM1 plus complement in vitro on cytotoxic T cell activities.
Stitz L; Baenziger J; Pircher H; Hengartner H; Zinkernagel RM
J Immunol; 1986 Jun; 136(12):4674-80. PubMed ID: 3486908
[TBL] [Abstract][Full Text] [Related]
6. Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice.
Cui FD; Asada H; Jin ML; Kishida T; Shin-Ya M; Nakaya T; Kita M; Ishii M; Iwai M; Okanoue T; Imanishi J; Mazda O
Gene Ther; 2005 Jan; 12(2):160-8. PubMed ID: 15470476
[TBL] [Abstract][Full Text] [Related]
7. Protection of neonatal mice against herpes simplex virus infection: probable in vivo antibody-dependent cellular cytotoxicity.
Kohl S; Loo LS
J Immunol; 1982 Jul; 129(1):370-6. PubMed ID: 6282968
[TBL] [Abstract][Full Text] [Related]
8. Frequency of herpes simplex virus-specific helper T lymphocyte precursors in the lymph node cells of infected mice.
Prymowicz D; Moore RN; Rouse BT
J Immunol; 1985 Apr; 134(4):2683-8. PubMed ID: 2579150
[TBL] [Abstract][Full Text] [Related]
9. Modified-self-induced modulation of the immune response to herpes simplex virus: effect on antibody formation, cytotoxic T lymphocyte induction, and survival.
Wilson LA; Karabin JM; Smith JW; Dawson D; Scott DW
J Immunol; 1984 Mar; 132(3):1522-8. PubMed ID: 6198395
[TBL] [Abstract][Full Text] [Related]
10. Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response.
Mitchell BM; Stevens JG
J Immunol; 1996 Jan; 156(1):246-55. PubMed ID: 8598469
[TBL] [Abstract][Full Text] [Related]
11. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.
Jamali A; Mahdavi M; Hassan ZM; Sabahi F; Farsani MJ; Bamdad T; Soleimanjahi H; Motazakker M; Shahabi S
Int Immunol; 2009 Mar; 21(3):217-25. PubMed ID: 19174474
[TBL] [Abstract][Full Text] [Related]
12. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
[TBL] [Abstract][Full Text] [Related]
13. In vivo significance of NK cell on resistance against virus (HSV-1) infections in mice.
Habu S; Akamatsu K; Tamaoki N; Okumura K
J Immunol; 1984 Nov; 133(5):2743-7. PubMed ID: 6207244
[TBL] [Abstract][Full Text] [Related]
14. Control of acute cutaneous herpes simplex virus infection: T cell-mediated viral clearance is dependent upon interferon-gamma (IFN-gamma).
Smith PM; Wolcott RM; Chervenak R; Jennings SR
Virology; 1994 Jul; 202(1):76-88. PubMed ID: 7912023
[TBL] [Abstract][Full Text] [Related]
15. Stress-induced effects on integral immune components involved in herpes simplex virus (HSV)-specific memory cytotoxic T lymphocyte activation.
Bonneau RH
Brain Behav Immun; 1996 Jun; 10(2):139-63. PubMed ID: 8811937
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of immunologic resistance to herpes simplex virus 1 (HSV-1) infection.
Rager-Zisman B; Allison AC
J Immunol; 1976 Jan; 116(1):35-40. PubMed ID: 173758
[TBL] [Abstract][Full Text] [Related]
17. Abrogation of anti-Pichinde virus cytotoxic T cell memory by cyclophosphamide and restoration by coinfection or interleukin 2.
Walker CM; Paetkau V; Rawls WE; Rosenthal KL
J Immunol; 1985 Aug; 135(2):1401-7. PubMed ID: 2989365
[TBL] [Abstract][Full Text] [Related]
18. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
[TBL] [Abstract][Full Text] [Related]
19. Defective production of anti-herpes simplex virus antibody by neonatal mice. Reconstitution with Ia+ macrophages and T helper lymphocytes from nonimmune adult syngeneic mice.
Kohl S; Thomas JW; Loo LS
J Immunol; 1986 Apr; 136(8):3038-44. PubMed ID: 3007609
[TBL] [Abstract][Full Text] [Related]
20. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection.
Martin S; Rouse BT
J Immunol; 1987 May; 138(10):3431-7. PubMed ID: 3033075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
